drugset / Trial / NCT00428844

Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

NCT00428844

Phase 2 Completed 75 enrolled Merck & Co., Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a research study designed to look at the efficacy and safety of daptomycin given at a dose of 6 mg/kg or 8 mg/kg in subjects being treated for prosthetic hip or knee infections caused by Staphylococci. These types of bacteria are among the most common types of bacteria causing infections of prosthetic joints.

Timeline

Start
2007-06-26
Primary completion
2010-03-26
Completion
2010-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 6 mg/kg Intravenous
Subject Daptomycin Other / unclassified 8 mg/kg Intravenous
Comparator FLOXACILLIN Small molecule 1 mg
Comparator FLOXACILLIN Small molecule 2 mg
Comparator Teicoplanin Other / unclassified 6 mg/kg
Comparator Vancomycin Other / unclassified 1 g
Comparator nafcillin Small molecule 1 g
Comparator nafcillin Small molecule 2 g
Comparator oxacillin Small molecule 1 g
Comparator oxacillin Small molecule 2 g

Indications